Antibe Therapeutics GAAP EPS of -C$0.11

Stock Information for Antibe Therapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Antibe Therapeutics

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Reports Q3 2024 Interim Financial and Operating Results
Antibe Extends Early Warrant Exercise Incentive Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.